A first time report on the coocurrence of sarcoidosis and ALK(−) CD30(+) anaplastic large cell lymphoma that is highly responsive to brentuximab vedotin treatment
Restricted accessCase reportFirst published online October, 2019
A first time report on the coocurrence of sarcoidosis and ALK(−) CD30(+) anaplastic large cell lymphoma that is highly responsive to brentuximab vedotin treatment
Sarcoidosis is known to be associated with higher incidence of solid tumors and hematological malignancies. ALK(−) CD30(+) anaplastic large cell lymphoma is a type of non-Hodgkin lymphoma showing poor prognosis, and seldom co-occurs with sarcoidosis. As this rare and highly mortal disease did not respond to classical chemotherapies and showed remission with brentuxumab vedontin treatment, we are presenting our first case reported from Turkey hoping to contribute to the literature.
IannuzziMCFontanaJR. Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. JAMA2011; 305: 391–399.
2.
MusellimBKumbasarOOOngenG, et al.Epidemiological features of Turkish patients with sarcoidosis. Respir Med2009; 103: 907–912.
3.
CatherHJrBahramSKhachemouneADermatologicdiseases. In: BaughmanR (ed). Sarcoidosis, New York: Taylor & Francis, 2006, pp. 593–604.
4.
CarasWEDillardTBakerT, et al.Coexistence of sarcoidosis and malignancy. South Med J2003; 96: 918–922.
5.
SeersholmNVestboJViskumK. Risk of malignant neoplasms in patients with pulmonary sarcoidosis. Thorax1997; 52: 892–894.
6.
BrinckerHWilbekE. The incidence of malignant tumours in patients with respiratory sarcoidosis. Br J Cancer1974; 29: 247–251.
7.
LondonJGradosAFerméC, et al.Sarcoidosis occurring after lymphoma: report of 14 patients and review of the literature. Medicine (Baltimore)2014; 93: e121–e121.
8.
ChalayerÉBachyEOccelliP, et al.Sarcoidosis and lymphoma: a comparative study. QJM2015; 108: 871–878.
9.
SutherlandMSSandersonRJGordonKA, et al.Lysosomal trafficking and cysteine protease metabolism confertarget-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem2006; 281: 10540–10547.
10.
JiJShuXLiX, et al.Cancer risk in hospitalized sarcoidosis patients: a follow-upstudy in Sweden. Ann Oncol2009; 20: 1121–1126.
11.
American Thoracic Society, Medical Section of the American Lung Association. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160:736–755.
12.
BrinckerH. The sarcoidosis-lymphoma syndrome. Br J Cancer1986; 54: 467–473.
13.
PapanikolaouICSharmaOP. The relationship between sarcoidosis and lymphoma. Eur Respir J2010; 36: 1207–1219.
14.
PrignanoFMoriMSantucciM, et al.CD30 + cutaneous T-cell lymphoma associated with sarcoidosis. J Eur Acad Dermatol Venereol1992; 1: 103–108.
15.
BrinckerH. Sarcoidosis and malignancy [Letter]. Chest1995; 108: 1472–1474.
16.
AsklingJGrunewaldJEklundA, et al.Increased risk for cancer following sarcoidosis. Am J Respir Crit Care Med1999; 160: 1668–1672.
17.
MasonDYHarrisNLDelsolG, et al.Anaplastic large cell lymphoma, ALK-negative. In: SwerdlowSHCampoEHarrisNL, et al.(eds). WHO classification of tumours of haematopoietic and lymphoid tissue, Lyon: IARC Press, 2008, pp. 317–319.
